trending Market Intelligence /marketintelligence/en/news-insights/trending/m1zfubWNr4XJACy0X-CnKQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

AstraZeneca's inhaled triple combo lung disease therapy gets approval in China

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

AstraZeneca's inhaled triple combo lung disease therapy gets approval in China

AstraZeneca PLC said its triple-combination therapy PT010 was approved in China for a group of lung diseases called chronic obstructive pulmonary disease, or COPD.

SNL Image

The medicine was approved as a maintenance therapy, which is meant to either complement the main treatment or be used as a follow-up. PT010 is a combination of inhaled corticosteroid budesonide, with long-acting muscarinic agonist glycopyrronium and long-acting beta2-agonist formoterol fumarate, delivered through a pressurized metered-dose inhaler.

The U.K.-based pharmaceutical giant said the approval by China's National Medical Products Administration follows a priority review by the regulator. The approval was backed by data from a phase 3 trial, dubbed Kronos, which showed that the therapy significantly improved lung function in patients with COPD.

The therapy, marketed as Breztri Aerosphere in Japan, was rejected by the U.S. Food and Drug Administration in October.